Pleural tuberculosis in Bhubaneswar, Odisha, during 2016 to 2022

Indian J Med Microbiol. 2023 Nov-Dec:46:100479. doi: 10.1016/j.ijmmb.2023.100479. Epub 2023 Oct 4.

Abstract

We conducted a retrospective study to evaluate the burden of tuberculosis and rifampicin resistance in patients with pleural effusion in Bhubaneswar, Odisha, during February 2016, to December 2022, using cartridge-based nucleic acid amplification test (CBNAAT, Xpert MTB/RIF). Of the 1370 pleural fluid samples tested at the National Reference Laboratory for tuberculosis, 3.8% (52/1370) were positive for M.tuberculosis. Rifampicin resistance was detected in 3.8% (2/52) samples. The positivity was 5% in 2016, increased to 7.5% in 2020, and was 4.4% in 2022. The positivity varied across age groups, ranging from 1.5% in patients aged >60 years to 6.1% in 15-30 years.

Keywords: CBNAAT; GeneXpert; Pleural effusion; Tuberculosis.

MeSH terms

  • Antibiotics, Antitubercular*
  • Humans
  • Mycobacterium tuberculosis* / genetics
  • Retrospective Studies
  • Rifampin / pharmacology
  • Rifampin / therapeutic use
  • Sensitivity and Specificity
  • Tuberculosis, Pleural* / drug therapy
  • Tuberculosis, Pleural* / epidemiology

Substances

  • Rifampin
  • Antibiotics, Antitubercular